Clinical trials: Seasonal Allergic Rhinitis (SAR)
Seasonal Allergic Rhinitis, SAR
Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies
The purpose of this study is to assess the safety and efficacy of an investigational nasal aerosol at two doses compared with placebo nasal aerosol in the treatment of seasonal allergic rhinitis in children (6-11 years of age).
- Trial name
- NCT01307319
- Testing
- BDP HFA
- Where
- 45 sites in United States
- Volunteers
- 715 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Seasonal Allergic Rhinitis
Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED)
This was a randomized, double-blind, parallel-group, multicenter study that used both an active control (fexofenadine) and a placebo control to evaluate desloratadine 5 mg once daily during a 15-day treatment period.
- Trial name
- NCT00783211
- Testing
- desloratadine, fexofenadine
- Volunteers
- 722 people
- Sponsor
- Organon and Co
Seasonal Allergic Rhinitis, Hay Fever
Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)
The purpose of the study is to assess the efficacy and safety of an investigational nasal aerosol compared with placebo nasal aerosol in the treatment of seasonal allergic rhinitis.
- Trial name
- NCT01024608
- Testing
- Beclomethasone dipropionate
- Where
- 4 sites in United States
- Volunteers
- 340 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Rhinitis, Allergic, Seasonal, Hay Fever
To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)
The primary objective of this study is to demonstrate the efficacy of ciclesonide applied as a nasal spray once daily in patients with SAR. The secondary objectives are to evaluate Quality-of-Life and safety.
- Trial name
- NCT00659841
- Testing
- Ciclesonide
- Where
- 6 sites in United States
- Volunteers
- 302 people
- Sponsor
- AstraZeneca
Seasonal Allergic Rhinitis
Trial of STAHIST in Seasonal Allergic Rhinitis
The overall development plan is to show that the combination of tried-and-proven decongestant/antihistamine ingredients (pseudoephedrine hydrochloride and chlorpheniramine maleate), plus a very small amount of belladonna…
- Trial name
- NCT01293201
- Testing
- STAHIST
- Where
- 8 sites in United States
- Volunteers
- 290 people
- Sponsor
- Magna Pharmaceuticals, Inc.
Seasonal Allergic Rhinitis
Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)
This study will examine dose ranging characteristics of bepotastine besilate nasal spray compared to placebo nasal spray in 600 male or female subjects 12 years of age and older with active seasonal allergic rhinitis (SAR) and a…
- Trial name
- NCT01753739
- Testing
- Bepotastine besilate
- Where
- United States
- Volunteers
- 617 people
- Sponsor
- Bausch & Lomb Incorporated
Seasonal Allergic Rhinitis (SAR)
Study of Stapokibart Injection in Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)
This study is a multicenter, single-arm, open-label, phase II study to evaluate the safety, pharmacokinetics, and immunogenicity of Stapokibart injection in Adolescent Patients with SAR.
- Trial name
- NCT07617324
- Testing
- Stapokibart injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Chengdu Kangnuoxing Biopharma,Inc.
Seasonal Allergic Rhinitis (SAR)
Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)
Study to evaluate the efficacy, safety and tolerability of GSP 301 nasal spray (NS) compared with placebo NS in pediatric subjects (aged 6 to under 12 years) with Seasonal Allergic Rhinitis (SAR).
- Trial name
- GSP 301-305 (NCT03463031)
- Testing
- GSP 301 NS
- Where
- 32 sites in United States
- Volunteers
- 446 people
- Sponsor
- Glenmark Specialty S.A.
Seasonal Allergic Rhinitis (SAR)
Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study aimed at evaluating the efficacy and safety of stapokibart in adolescent patients with seasonal allergic rhinitis, and observing the…
- Trial name
- NCT07678931
- Testing
- Stapokibart
- Where
- 27 sites in China
- Volunteers
- 136 people
- Sponsor
- Chengdu Kangnuoxing Biopharma,Inc.
Allergic Rhinitis, Hay Fever
Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)
The objective of this clinical trial was to assess the efficacy and safety of cetirizine HCl syrup vs. loratadine syrup vs. placebo syrup in the treatment of SAR in children 6 to 11 years old.
- Conditions
- Allergic Rhinitis, Hay Fever, SAR, Rhinitis, Allergic, Seasonal
- Trial name
- NCT02932774
- Testing
- Cetirizine, Loratadine
- Volunteers
- 683 people
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Seasonal Allergic Rhinitis
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)
This is a 2-week, multicenter, randomized, double-blind, placebo-controlled, parallel group, efficacy and safety study of ciclesonide nasal aerosol administered once daily to male and premenarchal female subjects 6 to 11…
- Trial name
- NCT01458275
- Testing
- Ciclesonide nasal aerosol 37 mcg, ciclesonide nasal aerosol 74 mcg
- Where
- 66 sites in United States
- Volunteers
- 847 people
- Sponsor
- Sumitomo Pharma America, Inc.
Seasonal Allergic Rhinitis
Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older
This clinical research study will evaluate the safety and effectiveness of two doses of an investigational medication (ciclesonide nasal aerosol) for the treatment of subjects with of seasonal allergic rhinitis (SAR).
- Trial name
- NCT01010971
- Testing
- Ciclesonide HFA 160 μg, Ciclesonide HFA 80 μg
- Where
- 7 sites in United States
- Volunteers
- 671 people
- Sponsor
- Sumitomo Pharma America, Inc.
Seasonal Allergic Rhinitis
New Nasal Applicator / New Formulation - User Study
The purpose of this study is to compare the efficacy of once daily dosing with Rhinocort Aqua (new formulation) against Rhinocort Aqua (current formulation) and placebo in reliving the symptoms of seasonal allergic rhinitis (SAR).
- Trial name
- NCT00641979
- Testing
- budesonide
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Seasonal Allergic Rhinitis, Hayfever
Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR
This is a phase 2, randomized, double-blind, placebo-controlled, parallel-group, 2-week, multi-center, dose-range-finding study in male or female patients (12 years and older) with SAR.
- Trial name
- NCT00854360
- Testing
- Beclomethasone dipropionate HFA Nasal Aerosol
- Where
- 26 sites in United States
- Volunteers
- 487 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Rhinitis, Allergic, Seasonal
Efficacy and Safety of Levocetirizine 8 Weeks Prior and After the Onset of the Grass Pollen Season in Subjects With SAR
Efficacy and Safety of Levocetirizine 8 Weeks Prior and After the Onset of the Grass Pollen Season in Subjects With SAR
- Trial name
- NCT00521040
- Testing
- Levocetirizine dihydrochloride
- Volunteers
- 459 people
- Sponsor
- UCB Pharma
Seasonal Allergic Rhinitis
To Study GSP 301 in Patients With Seasonal Allergic Rhinitis
Study to evaluate the two different strengths and dose regimen of GSP 301 to be effective in treatment of seasonal allergic rhinitis.
- Trial name
- NCT02318303
- Testing
- GSP 301-1 NS (QD), GSP 301-2 NS (BID), Olopatadine HCl-1 NS (QD)
- Where
- 10 sites in United States
- Volunteers
- 1,111 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Seasonal Allergic Rhinitis
Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis
To demonstrate the efficacy of ciclesonide HFA applied as a nasal aerosol (160 μg and 80 μg) once daily compared to placebo in subjects with SAR.
- Trial name
- NCT00790023
- Testing
- 80 mcg Ciclesonide, 160 mcg Ciclesonide
- Where
- 4 sites in United States
- Volunteers
- 707 people
- Sponsor
- Sumitomo Pharma America, Inc.
Seasonal Allergic Rhinitis
A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)
The objectives of this study is to demonstrate bioequivalence (comparable safety and efficacy) of the Test product to the Reference in the treatment of subjects seasonal allergic rhinitis.
- Trial name
- NCT01673659
- Testing
- Mometasone furoate, Nasonex Nasal Spray
- Where
- United States
- Volunteers
- 1,220 people
- Sponsor
- Padagis LLC
Rhinitis, Allergic, Seasonal
Once-Daily Investigational Nasal Spray In Adults And Adolescents With Seasonal Allergic Rhinitis (SAR)
Allergic rhinitis is an inflammatory disorder of the upper airway that occurs following allergen exposure. The focus of this study, seasonal allergic rhinitis (SAR), is one type of allergic rhinitis that is triggered by the…
- Trial name
- NCT00197262
- Testing
- GW685698X Aqueous Nasal Spray
- Where
- 18 sites in United States
- Volunteers
- 288 people
- Sponsor
- GlaxoSmithKline
Hay Fever, Seasonal Allergic Rhinitis
Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)
The aim of the study is to determine the efficacy and safety of ciclesonide nasal spray in children with seasonal allergic rhinitis. Ciclesonide will be administered intranasally at two dose levels once daily.
- Trial name
- NCT00305487
- Testing
- Ciclesonide nasal spray
- Where
- 71 sites in United States
- Volunteers
- 660 people
- Sponsor
- AstraZeneca